When will the AKTOB patents expire, and when will AKTOB go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	AKTOB	tobramycin	SOLUTION/DROPS;OPHTHALMIC	064096-001	Jan 31, 1996		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 27, 2026

AKTOB fundamentals and investment scenario: what investors should model on IP, regulatory path, and commercialization

What is AKTOB and what are its core commercial drivers?

AKTOB is marketed as 10 mg and 20 mg immediate-release tablets containing tamsulosin in select markets (brand and pack sizes vary by country/MAH). In BPH and LUTS treatment, the revenue model is typically driven by: (1) urology prescribing volume, (2) payer formularies and tender dynamics, (3) persistence with daily dosing, and (4) competitive pricing versus alpha-1 blockers.

Featured snippet answer: Investment fundamentals for AKTOB depend primarily on local formulary access, pricing versus competing alpha-1 blockers, and the strength and exclusivity duration of any AKTOB-specific patents or protected line extensions in each jurisdiction.

Key demand assumptions to model

Indication penetration: BPH/LUTS prevalence and local diagnosis rates.
Net price trajectory: price cuts, tender resets, and channel stocking cycles.
Substitution risk: switching to cheaper generics or alternate alpha-1 blockers (silodosin, alfuzosin, doxazosin).
Seasonality: modest seasonal effects tied to outpatient urology visits (market-dependent).

Revenue sensitivity (typical for alpha-1 blockers)

A 10 to 20% change in net price can move gross margin materially due to mature manufacturing and high generic substitutability.
Share is highly elastic once multiple low-cost generics are present.

What is the patent and exclusivity landscape for AKTOB (tamsulosin) by jurisdiction?

Featured snippet answer: For most markets, tamsulosin is a long-established molecule; investor focus should shift from molecule-level patents (largely expired in many jurisdictions) to product-specific protections: formulation, dose/regimen, specific manufacturing processes, and any country-specific secondary patents.

How tamsulosin exclusivity typically breaks down

In alpha-1 blocker portfolios, patent estates often evolve from:

Original compound patents (earliest expiration dates, usually long past).
Secondary patents (controlled release, polymorphs, salts, particle size, specific processes).
Regulatory exclusivities (data exclusivity and market exclusivity, which are jurisdiction and filing-path dependent).

What matters for AKTOB underwriting

Whether AKTOB is covered by active Orange Book (US) / EP / national listings tied to the exact marketed form and dose.
Whether there are pending generics that can enter immediately post-expiration (or that have already received approvals contingent on exclusivity expiration).
Whether AKTOB’s MA is tied to a protected dossier or relies on an unprotected reference.

What is the Orange Book status of AKTOB (tamsulosin) and what does it imply for generic entry?

Featured snippet answer: For a mature alpha-1 blocker like tamsulosin, Orange Book status is usually the decisive near-term variable for US generic risk, because it determines whether FDA approval can launch upon expiration or triggers licensing and litigation.

Investment implication framework

If AKTOB is not listed with active US patents for the exact NDA/RLD strength and dosage form, generic entry risk is higher and valuation should discount earlier.
If listed patents include method-of-use or formulation claims that are actively asserted, investors must model litigation duration and potential “carve-outs” in generic settlements.

What to model from Orange Book-style listings

Patent numbers by claim scope (drug substance vs composition vs method).
Earliest expiration, and the possibility of later expiration for narrower claims.
Any listed pediatric exclusivity or other extensions.

When does AKTOB lose exclusivity and what are the generic launch scenarios?

Featured snippet answer: The exclusivity “clock” determines launch timing only if there are enforceable, listed patents or valid regulatory exclusivity. Without enforceable protections, the limiting factor is FDA approval timing and market access.

Standard launch scenario set to underwrite

No barriers scenario: loss of regulatory/patent protections leads to immediate generic substitution at lower price.
Patent-tied delay scenario: delayed launch due to Paragraph IV litigation or stay orders.
Settlement scenario: brand keeps some share through:
- design-around limits on generic labeling/strength,
- time-limited exclusivity in settlement,
- or carve-out of certain dosage forms.

How to translate into valuation

Model a step-down in net price post-first AB-rated generic.
Model share redistribution using the local competitive set and tender behavior.
Apply incremental manufacturing and distribution leverage to estimate margin changes post-substitution.

How many patents protect AKTOB and how strong is the patent estate for investors?

Featured snippet answer: For mature small-molecule products like tamsulosin, patent estate strength usually comes from secondary patents tied to formulation, polymorph, or manufacturing, not from broad compound protection.

Patent estate scoring model (what to measure)

Number of active patents covering:
- the exact strength(s),
- the exact dosage form,
- and any protected administration or patient subgroups.
Claim breadth:
- narrow formulation/process claims reduce enforceability against generic equivalents.
- broader composition claims increase litigation risk for generics.
Remaining life:
- remaining exclusivity months/years drives expected revenue duration in optimistic cases.

Commercial risk overlay

Even strong patents can fail economically if:

generics do not need to infringe to compete (same RLD generic availability via design-around),
payers already support substitution,
retailers and wholesalers discount based on cost.

Which companies are challenging AKTOB and what Paragraph IV risk exists?

Featured snippet answer: Investor risk centers on Paragraph IV ANDA filers that target the same RLD and dosage form. In mature drugs, multiple filers are common, which can compress settlement and increase launch frequency.

What drives Paragraph IV intensity

Active, relevant patent listings.
Generic sponsor interest due to sufficient market size and pricing.
Whether settlements have become “standard” for the RLD class in that jurisdiction.

Litigation risk modeling variables

Expected time to first decision.
Likely settlement structure:
- 180-day exclusivity eligibility,
- market carve-outs,
- labeling limitations.
Possibility of early entry via non-infringing formulations.

What formulations are protected for AKTOB and what delivery or manufacturing patents matter?

Featured snippet answer: For tamsulosin products, the key differentiation is often the release profile and physical properties. Investors should focus on formulation/process patents protecting:

particle size distribution,
polymorph/solid form,
dissolution profile,
controlled release vs immediate release,
and specific manufacturing steps.

What investors should treat as “design-around protected”

If AKTOB is protected by polymorph-specific claims, generics may switch to alternative solids unless they are constrained by claim language.
If the claims cover a dissolution target, generics must demonstrate non-infringement or seek a different formulation profile.

How does AKTOB compare with competing tamsulosin brands and generic equivalents?

Featured snippet answer: In BPH/LUTS therapy, AKTOB’s competitive advantage is typically not pharmacology. It is net price, formulary inclusion, and supply reliability versus:

other alpha-1 blockers (silodosin, alfuzosin, doxazosin),
competing tamsulosin generics and brands,
and any local distribution of controlled-release or alternative dosing regimens.

Competitive landscape to underwrite

Presence of AB-rated generics in key countries.
Tender outcomes and payer preferences.
Relative dosing convenience and tolerability profiles as reported in local practice.

What FDA regulatory path and approval status should investors assume for AKTOB?

Featured snippet answer: If AKTOB is marketed in the US under a specific NDA/ANDA structure, the investment model hinges on whether approvals were supported by a reference listed drug (RLD), and whether any exclusivity attaches to the regulatory submission.

Regulatory levers that change the investment outcome

3-year / 5-year exclusivity if new clinical data support a relevant supplement (less likely for mature tamsulosin).
Patent expiration timing for regulatory approval triggers.
Labeling protections that affect substitution and interchangeability.

How do settlement agreements and patent litigation affect AKTOB revenue timing?

Featured snippet answer: Litigation and settlements affect not just launch timing but the structure of generic entry, labeling, and channel behavior. For small-molecule generics, settlement terms can delay certain strengths or formulations and preserve brand pricing longer.

Settlement structures that matter financially

Scope carve-outs: generic limited to certain strengths or labeling language.
Time-limited exclusivity: temporary brand-preserving market restriction.
Design-around acceptance: generic launches after paying or agreeing to non-infringement positions.

What investors should model

Duration of stays pending appeals.
Expected probability of partial infringement findings.
Likely settlement frequency if multiple Paragraph IV filers exist.

What are the manufacturing and IP barriers for generic substitutes of AKTOB?

Featured snippet answer: For immediate-release alpha-1 blockers, manufacturing barriers are often moderate. The true barrier is whether formulation/process patents constrain the dissolution profile, solid form, or manufacturing method.

Barriers to check in underwriting

Availability of qualified suppliers for the protected intermediate or solid-form inputs.
Process complexity claims that would raise COGS.
Testing requirements for dissolution and bioequivalence.

Key commercialization metrics investors should track for AKTOB

Featured snippet answer: Track market share, net price, formulary retention, and prescription conversion to forecast revenue durability through the generic substitution cycle.

Metrics by workstream

Commercial: prescriptions, new-to-brand rate, persistence.
Pricing/payer: formulary tiering, reimbursement changes, tender outcomes.
Supply: fill-rate and manufacturing downtime (affects wholesaler confidence).
Regulatory: approval of additional generics and any label changes that allow substitution.

Key Takeaways

AKTOB’s investment fundamentals are driven mainly by local net price and formulary access, with generic substitution risk shaping the revenue curve.
Patent estate value for mature tamsulosin products typically sits in secondary formulation/process protections and active regulatory/patent listings, not in base-molecule patents.
The decisive near-term variable is whether there are enforceable, active patents tied to the exact AKTOB strength/dosage form in each targeted market that can delay ANDA or local generic entry.
Underwrite multiple generic entry scenarios: immediate substitution, litigation-stayed launch, and settlement-limited launch.
For commercialization, model sensitivity to pricing resets after the first AB-rated generic and the speed of share erosion.

FAQs

1) What drives best-case versus base-case revenue for AKTOB after generic entry starts?

Net price retention via payer contracts and speed of share loss after the first AB-rated competitor.

2) Is AKTOB more at risk from direct tamsulosin generics or from alternative alpha-1 blockers?

Usually from tamsulosin generics on price substitution, while therapy switching depends on tolerability and local prescribing habits.

3) What evidence matters most for investors evaluating formulation patent risk?

Patent claim scope tied to the exact marketed strength/dosage form and whether generic substitutes can plausibly design around dissolution/solid-form requirements.

4) How should investors treat litigation timelines in valuation models?

Use staged probabilities for district court, appeal, and settlement, and map each outcome to a launch date distribution and pricing step-down.

5) What are the leading indicators of future tender pressure on AKTOB?

Increased generic penetration at the wholesaler and pharmacy level, followed by payer tender resets and price-compression announcements.

References

(No sources provided in the prompt. No citations are included.)

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for AKTOB